Forbes November 27, 2020
Bruce Y. Lee

The past few weeks have been sort of like first dates with three different Covid-19 coronavirus vaccines. They were positive first dates, but first dates nonetheless.

Since November 9, three vaccine manufacturers, Pfizer, followed by Moderna and then AstraZeneca, have offered some preliminary results from their Phase 3 clinical trials. And those numbers have looked good. Pfizer mentioned a vaccine efficacy of above 90% for its mRNA-based vaccine candidate, BNT162b2, Moderna a vaccine efficacy of 94.5% for its mRNA-1273, and AstraZeneca a vaccine efficacy of up to 90% for its AZD1222.

Ninety percent is an impressive number. However, before you say, “you had me at 90%,” keep in mind that these are still very preliminary results. Don’t start dreaming about...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health / COVID
The Ripple Effect: Ways to Make Health in All Policies Stick in Kansas and Beyond to Enhance Health and Equity
Research Funding Is Needed To Support An Effective, Equitable, And Sustainable Public Health System
Covid’s scientific silver lining: A chance to watch the human immune system respond in real time
New Data: Long COVID Cases Surge
New federal health IT strategy increases focus on public health, AI

Share This Article